Skip to main content
Psych Congress  
2018

Dasotraline for Treatment of Adults With Binge-eating Disorder: Effect on Behavioral Outcomes - Week 2

Authors  

Brad Navia, MD, PhD – Sunovion Pharmaceuticals Inc.; James Hudson, MD, ScD, SM – 2McLean Hospital & Harvard Medical School, Belmont, MA; Susan McElroy, MD – Lindner Center of HOPE, Mason, OH; and University of Cincinnati College of Medicine, Cincinnati, OH ; Ling Deng, PhD – Sunovion Pharmaceuticals Inc.; Seth Hopkins, PhD – Sunovion Pharmaceuticals Inc.; Kenneth Koblan, PhD – Sunovion Pharmaceuticals Inc.; Antony Loebel, MD – Sunovion Pharmaceuticals Inc.; Robert Goldman, PhD – Sunovion Pharmaceuticals Inc.

Sponsor  
Sunovion Pharmaceuticals Inc.Clinicaltrials.gov number: NCT02564588

Objective: To evaluate the efficacy of dasotraline in the treatment of secondary behavioral and psychological outcomes in patients with Binge-eating disorder (BED).

Methods: Patients with BED (N=317) were randomized, double-blind, to 12 weeks of treatment with flexible doses of dasotraline (4, 6, and 8 mg/d), or placebo. The primary efficacy measure was number of binge eating (BE) days/week. Secondary outcomes included the Yale-Brown Obsessive-Compulsive Scale Modified for Binge Eating (Y-BOCS-BE); and the Eating Disorder Examination Questionnaire Brief Version (EDE-Q7), which consists of a global score, and 3 subscale scores (dietary restraint, shape concern, and weight concern).

Results: Mean reduction from baseline in number of BE days/week was significantly greater for dasotraline vs. placebo at week 12 (-3.74 vs. -2.75; P<0.0001). Mean endpoint change was significantly greater for the dasotraline vs. placebo on the Y-BOCS-BE total score (-17.05 vs. -9.88; P<0.0001), the obsession subscale score (-8.32 vs. -4.58; P<0.0001), and the compulsion subscale score (-8.69 vs. -5.35; P<0.0001). Mean endpoint change was also significantly greater for dasotraline vs. placebo on the EDE-Q7 global score (-0.85 vs. -0.23; P<0.001), and dietary restraint (-0.55 vs. +0.15; P<0.001), shape concern (-0.93 vs. -0.43; P=0.011), and weight concern (-1.03 vs. -0.44; P=0.003) subscale scores.

Conclusions: In this 12-week study of BED patients, treatment with dasotraline (4-8 mg/d) was associated with significant improvement in behavioral and psychological outcomes, including measures of obsessions and compulsions, and weight and shape concerns associated with BED, and intensity of attempts to restrict food intake.

Back to Top